Biosimilar Development: from Science to Market
نویسنده
چکیده
The biotechnology industry has established itself as a major source of new human therapeutic protein drugs which can be described as complex biological entities. The majority of these in production, such as erythropoeitin (EPO), interleukin-2 (IL-2), interferon (IFN), granulocyte colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF) and tissue plasminogen activator (TPA), occur naturally in the form of glycoproteins.
منابع مشابه
Presentation of a Novel Model for Evaluation of Commercialization of Research and Development: Case Study of the Pharmaceutical Biotechnology Industry
Abstract Background and scope: The current situation in Iran suggests a good basis for advancement in biotechnology industries because the patents for many hi-tech medicines registered in developed countries are ending. Biosimilar and technology-oriented companies without patents will have the opportunity to enter the biosimilar market and move toward innovative initiatives. The present researc...
متن کاملPresentation of a Novel Model for Evaluation of Commercialization of Research and Development: Case Study of the Pharmaceutical Biotechnology Industry
Abstract Background and scope: The current situation in Iran suggests a good basis for advancement in biotechnology industries because the patents for many hi-tech medicines registered in developed countries are ending. Biosimilar and technology-oriented companies without patents will have the opportunity to enter the biosimilar market and move toward innovative initiatives. The present researc...
متن کاملThe Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape
Background: Biopharmaceutical medicines represent a growing share of the global pharmaceutical market, and with many of these biopharmaceutical products facing loss of exclusivity rights, also biosimilars may now enter the biopharmaceutical market. Objectives: This study aims to identify and document which investment and development strategies are adopted by industrial players in the global bio...
متن کاملKey drivers for market penetration of biosimilars in Europe
Background & Objectives: Potential drivers and barriers of biosimilar uptake were mainly analysed through qualitative approaches. The study objective was to conduct a quantitative analysis and identify drivers of biosimilar uptake of all available biosimilars in the European Union (EU). Methods: A three-step process was established to identify key drivers for the uptake of biosimilars in the to...
متن کاملPatient Perspectives on Biosimilar Insulin.
Given that a new wave of biosimilar insulins will likely enter the market in coming years, it is important to understand patient perspectives on these biosimilars. A survey (N = 3214) conducted by the market research company dQ&A, which maintains a 10 000-patient panel of people with type 1 or type 2 diabetes in roughly equal measure, investigated these perspectives. The survey asked whether pa...
متن کاملOvercoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies
BACKGROUND In 2014, six of the top ten blockbuster medicines were monoclonal antibodies. This multibillion-dollar market with expiring patents is the main driver for the development of biosimilar mAbs. With the ever-increasing cost of healthcare and the economic pressure to reduce or sustain healthcare expenses, biosimilars could be instrumental in reducing costs for medication and increasing p...
متن کامل